Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$21.20 +1.0%	$19.24	$15.47 ▼ $36.37	$725.32M	1.47	186,739 shs	310,649 shs
RCKT Rocket Pharmaceuticals	$2.48 -5.3%	$6.32	$2.19 ▼ $26.98	$264.83M	1.02	1.87 million shs	7.40 million shs
REPL Replimune Group	$8.93 -4.7%	$8.42	$4.93 ▼ $17.00	$688.39M	0.68	938,949 shs	2.18 million shs
SCPH scPharmaceuticals	$3.54 -0.3%	$2.67	$1.94 ▼ $5.65	$186.88M	0.17	366,966 shs	288,816 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	+4.79%	+1.79%	+0.48%	-11.05%	+11.82%
RCKT Rocket Pharmaceuticals	+5.65%	-60.06%	-64.01%	-72.28%	-87.32%
REPL Replimune Group	+11.15%	+6.96%	-0.21%	-26.10%	+87.03%
SCPH scPharmaceuticals	-0.84%	+1.14%	+49.79%	+8.23%	-9.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.1953 of 5 stars	3.6	0.0	0.0	2.8	0.0	0.0
RCKT Rocket Pharmaceuticals	4.8022 of 5 stars	4.2	2.0	4.7	2.0	5.0	1.3
REPL Replimune Group	4.1166 of 5 stars	3.6	1.0	4.5	3.1	2.5	0.6
SCPH scPharmaceuticals	3.9398 of 5 stars	3.5	1.0	4.2	3.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	85.31% Upside
RCKT Rocket Pharmaceuticals	2.44	Hold	$21.21	755.41% Upside
REPL Replimune Group	3.13	Buy	$19.43	117.57% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	295.48% Upside

Current Analyst Ratings Breakdown

Latest SCPH, AVBP, RCKT, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00
5/28/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $17.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$6.26 per share	N/A
SCPH scPharmaceuticals	$41.98M	4.45	N/A	N/A	$1.04 per share	3.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	8/13/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)
REPL Replimune Group	-$215.79M	-$3.07	N/A	N/A	N/A	N/A	-54.84%	-42.97%	8/6/2025 (Estimated)
SCPH scPharmaceuticals	-$54.81M	-$1.91	N/A	N/A	N/A	-264.60%	-244.93%	-68.56%	8/13/2025 (Estimated)

Latest SCPH, AVBP, RCKT, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/14/2025	Q1 2025	SCPH scPharmaceuticals	-$0.28	-$0.34	-$0.06	-$0.37	$11.63 million	$11.75 million
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/19/2025	Q4 2024	SCPH scPharmaceuticals	-$0.40	-$0.35	+$0.05	-$0.35	$12.08 million	$12.15 million
3/3/2025	Q4 2024	AVBP ArriVent BioPharma	-$0.78	-$0.60	+$0.18	-$0.61	N/A	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05
REPL Replimune Group	0.14	11.43	11.43
SCPH scPharmaceuticals	1.66	8.08	6.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
RCKT Rocket Pharmaceuticals	98.39%
REPL Replimune Group	92.53%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	N/A
RCKT Rocket Pharmaceuticals	24.76%
REPL Replimune Group	8.80%
SCPH scPharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable
REPL Replimune Group	210	77.09 million	70.24 million	Optionable
SCPH scPharmaceuticals	30	52.79 million	47.28 million	Optionable

SCPH, AVBP, RCKT, and REPL Headlines

Recent News About These Companies

BNP Paribas Financial Markets Increases Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 29 at 3:20 AM | marketbeat.com

Woodline Partners LP Sells 203,808 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

May 28 at 4:30 AM | marketbeat.com

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

May 22, 2025 | seekingalpha.com

Stonepine Capital Management LLC Has $2.42 Million Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 20, 2025 | marketbeat.com

Leerink Partnrs Has Bearish Forecast for SCPH Q2 Earnings

May 20, 2025 | americanbankingnews.com

Leerink Partnrs Analysts Lower Earnings Estimates for SCPH

May 20, 2025 | marketbeat.com

Suvretta Capital Management LLC Reduces Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 19, 2025 | marketbeat.com

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 16, 2025 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.com

scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2025 | zacks.com

scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | globenewswire.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Stake Reduced by J. Goldman & Co LP

May 14, 2025 | marketbeat.com

Insights Ahead: scPharmaceuticals's Quarterly Earnings

May 13, 2025 | benzinga.com

scPharmaceuticals (SCPH) Expected to Announce Quarterly Earnings on Tuesday

May 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, AVBP, RCKT, and REPL Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$21.20 +0.20 (+0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$21.26 +0.06 (+0.28%)

As of 04:20 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.48 -0.14 (-5.34%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.02 (+0.81%)

As of 06:16 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Replimune Group NASDAQ:REPL

$8.93 -0.44 (-4.70%)

Closing price 04:00 PM Eastern

Extended Trading

$8.98 +0.04 (+0.50%)

As of 05:49 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

scPharmaceuticals NASDAQ:SCPH

$3.54 -0.01 (-0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$3.57 +0.03 (+0.88%)

As of 04:10 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time